Table 31: UK Recent Past, Current & Future Analysis for Gene Amplification
Technologies by Segment - Polymerase Chain Reaction (PCR) and Other Gene Amplification
Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) III-27
Correlation Between HER-2/neu Gene Amplification
Evaluated by FISH and HER-2/neu Overexpression Assessed by IHC in 100 Node-Negative Breast Malignant Tumors(*) HER-2/neu Gene HER-2/neu Amplification (FISH), Expression No.
The purpose of this trial is to evaluate the safety and efficacy of MGCD265 administered to selected patients with specific activating MET driver mutations, MET gene amplification
, and MET or Axl gene rearrangements.
3) HER2/neu gene amplification
and protein overexpression in GGEAC were first described in 1986 (5,6) and were confirmed in subsequent studies.
The results of both the 2- and 3-tier systems have confirmed the significant association of Her-2 gene amplification
with poorer prognosis, independent of tumor size, grade, and receptor status.
Used in conjunction with expression microarrays, GenoSensor genomic microarrays can help researchers determine not only if a gene is present, but also whether the gene is found in abnormally high numbers, and if abnormal gene amplification
is correlated with overexpression of an important protein.
Tlsty has examined gene amplification
, in which cells make multiple copies of a particular gene, and has observed that this process occurs in about one in a billion healthy cells but in as many as one in 100 tumor cells.
Among the major developments in the recent years, gene amplification
technology indicates the highest potential growth.
AR gene amplification
and overexpression can make cells hypersensitive to low levels of androgen, and many prostate cancers show overexpression of AR (Taplin and Balk 2004; Visakorpi et al.
The Company now has four technology platforms: 1) Synthetic immunomodulatory oligonucleotide (IMOTM) motifs that act to modulate responses of the immune system; 2) Antisense technology which uses synthetic DNA to block the production of disease-causing proteins at the cellular level; 3) Synthetic DNA drug candidates that enhance the antitumor activity of certain marketed anticancer drugs, thereby increasing their effectiveness; and 4) Cyclicon probes, novel synthetic DNA structures for identifying gene function, which can be used for target validation and drug discovery as well as for PCR-based gene amplification
PCR conditions for pap31 gene amplification
were a single hot-start cycle at 95[degrees]C for 5 min, followed by 45 cycles of denaturing at 94[degrees]C for 45 s, annealing at 58[degrees]C for 45 s, and extension at 72[degrees]C for 45 s.
Tokyo, Japan, Sept 12, 2005 - (JCNN) - Sanko Junyaku announced on September 12 that its proprietary gene amplification
method was officially patented in the EU as of September 7.